Brief: Aptevo Therapeutics Says In Preclinical Studies APVO711 Demonstrates Dual Anti-Cancer Functionality
08/05/2025 17:23
May 8 (Reuters) - Aptevo Therapeutics Inc APVO.O: APTEVO THERAPEUTICS : IN PRECLINICAL STUDIES APVO711 DEMONSTRATES DUAL ANTI-CANCER FUNCTIONALITY WITH BROAD SOLID TUMOR POTENTIAL & DEVELOPABILITY ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Aptevo Therapeutics
See all newsBrief: Aptevo Therapeutics - Enters Amendment No. 6 To Rights Agreement On October 23, 2026 - SEC Filing
U.S. STOCKS ON THE MOVE-Principal Financial Group, NetApp
U.S. STOCKS ON THE MOVE-Genesco, Fervo Energy, Tyson Foods
Aptevo Therapeutics reports early data for blood cancer therapy; shares fall
Aptevo Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary